publication date: Mar. 29, 2019
Issue 13 - Mar. 29, 2019
To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.
  • Guest Editorial

    NCCN validates path toward de-escalated doses and reduced costs of cancer Drugs

    The ever-rising cost of oncology drugs is doing damage to cancer care on many levels.

    Annual total cost increases are projected to be as much as 20 percent annually. The intense financial pressure these costs place on our patients, even well-insured patients, is well documented.

  • Cancer is a model for drug development, FDA-bound Sharpless says to NCI advisors

    Decades of basic research in oncology are paying off, resulting in an unprecedented number of drug approvals, said Ned Sharpless, the NCI director who is set to become FDA acting commissioner.

  • Guest Editorial

    Congress must commit to sustained increases for NCI

    Cancer is a relentless disease that impacts millions of Americans.

    Just this year more than 1.7 million people in the U.S. are expected to be diagnosed with cancer, and over 600,000 Americans will die from the disease.

  • Letter to the Editor

    Gundry: saguaro cacti do not grow in Texas

    enjoy your publication and read it cover to cover most weeks. But I must point out a glaring error in your recent edition of March 22. The illustrations accompanying the article about the Texas cancer researchers show saguaro cacti. Saguaro cacti only grow in the Sonoran desert of southern Arizona and western Sonora, Mexico, with a few stray saguaros in California. The saguaro cactus does not grow in Texas. It is a common misconception that the saguaro grows throughout the west. The cactus is so unique to Arizona that the saguaro cactus blossom has been named the state flower of Arizona. I thought you should be made aware of this inaccuracy.

  • AACR News

    • Antoni Ribas named AACR president-elect for 2019-2020 term
    • Daniel Von Hoff, Louis Weiner, Nancy Goodman to receive AACR Distinguished Public Service Awards
    • AACR announces 2019 Class of Fellows of the AACR Academy
  • In Brief

    • Sara Hook named associate director for NCI at Frederick
    • GW Cancer Center receives $4M award for technical assistance to CDC National Comprehensive Cancer Control Program grantees
    • Groups urge Congress to close Medicare loophole for colorectal cancer screenings
    • Ali McBride to serve as ACCC president 2019-2020
  • Funding Opportunities

    DoD Kidney Cancer Research Program- Funding Opportunities for FY19

    The FY19 Defense Appropriation provides $20 million to the Department of Defense Kidney Cancer Research Program to support research of exceptional scientific merit in the area of kidney cancer. 

  • TCCL Logo

  • Conversation with The Cancer Letter

    Lee Schwartzberg tells us how three practices banded together to adapt to today’s cancer care and data revolution

    Community oncology needs to adapt to the era of precision oncology and Big Data, said Lee Schwartzberg, executive director of Memphis-based West Cancer Center, who was recently named medical director of OneOncology, a partnership between three oncology practices located in Tennessee and New York.

  • Clinical Roundup

    • Fulvestrant plus Anastrozole extends lives of women with advanced HR+ breast cancer
    • Study finds heating up tumors could make CAR-T therapy more effective
    • Study shows patients with or without cancer use different forms of marijuana
    • Study may explain why immunotherapy not effective for some patients with metastatic melanoma and kidney cancer
  • Drugs & Targets

    • FDA advances policy changes to modernize mammography services
    • FDA issues alert on the investigational use of Venclexta in multiple myeloma
    • Janssen submits application for Darzalex combination in multiple myeloma
    • Breath Diagnostics, Mayo collaborate to develop diagnostic using patients’ exhaled breath to detect lung cancer
    • Oncoceutics and NCI partner to develop ONC206
    • Elicio Therapeutics launches vaccine & immunotherapy platform

Copyright (c) 2018 The Cancer Letter Inc.